Skip to main content
. 2018 Jun 1;29(8):2234–2243. doi: 10.1681/ASN.2018020184

Figure 2.

Figure 2.

C5b9 formation normalized on resting but not activated human microvascular endothelial cells of dermal origin (HMEC-1) at the time of quiescent disease, whereas eculizumab blocked C5b9 to form. (A) C5b9 formation on resting and ADP-activated HMEC-1 after incubation with serum from patients with hypertension-associated thrombotic microangiopathy (TMA) at the time of acute disease (n=7), quiescent disease (n=4), and/or during eculizumab treatment (Ecu; n=5 or n=4, respectively); individual data are shown in Table 3. (B) Representative immunofluorescence microscopy images of either resting or ADP-activated HMEC-1 exposed to sera from patients with hypertension-associated TMA at the time of quiescent disease and healthy control (HC; i.e., normal human serum[NHS]). *P<0.01 versus NHS run in parallel; ***P<0.001 versus NHS run in parallel; ^^P<0.01 versus quiescent disease samples. DAPI, 4',6-diamidino-2-phenylindole.